Medical Communications
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
June 18, 2024 Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia
AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment
June 17, 2024 Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer
CytoSorbents announces EU launch and availability of PuriFi blood pump
June 14, 2024 Medical Communications CytoSorbents, EU, Haematology, PuriFi, blood pump
Tracon shares data from phase 2 trial for glioblastoma treatment
June 12, 2024 Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
June 11, 2024 Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
June 11, 2024 Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera
GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients
June 10, 2024 Medical Communications FDA, GSK, Immunology, Vaccine
FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia
June 7, 2024 Medical Communications FDA, Geron, Haematology, anaemia, mds
AbbVie initiates phase 3 multiple myeloma trial
June 6, 2024 Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
Quince Therapeutics gains FDA Fast Track Designation for EryDex System
June 4, 2024 Medical Communications EryDex, FDA, Quince Therapeutics, Rare Diseases, fast track designation
Oryzon Genomics announces publication of phase 2a ALICE trial results
June 4, 2024 Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment
June 3, 2024 Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024 Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases
May 30, 2024 Medical Communications Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases
Full-Life Technologies’ IND application for prostate cancer cleared by FDA
May 30, 2024 Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer
Latest content
